|
A phase Ib/II open label study of IMU-131 HER2/Neu peptide vaccine plus cisplatin and either 5-fluorouracil or capecitabine chemotherapy in patients with HER2/Neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction. |
|
|
|
Stock and Other Ownership Interests - Imugene |
|
Consulting or Advisory Role - Imugene |
Research Funding - Imugene |
Patents, Royalties, Other Intellectual Property - Imugene |
|
|
|
|
Stock and Other Ownership Interests - Imugene; Kazia Therapeutics; Living Cell Technologies |
Consulting or Advisory Role - Imugene; Kazia Therapeutics |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Arensia Exploratory Medicine |
Consulting or Advisory Role - ARENSIA Exploratory Medicine |
Research Funding - ARENSIA Exploratory Medicine |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb |
Consulting or Advisory Role - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - AstraZeneca |
|
|
|
|
Stock and Other Ownership Interests - Imugene |
|
Consulting or Advisory Role - Coleman Consultants; Imugene |
Travel, Accommodations, Expenses - Imugene |
Other Relationship - Imugene |
|
|
|
|
Stock and Other Ownership Interests - Imugene |
Research Funding - Imugene |
Patents, Royalties, Other Intellectual Property - Imugene |
Travel, Accommodations, Expenses - Imugene |